TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07542314: Study to Evaluate the Safety and Effectiveness of ELEVIDYS in Participants With Duchenne Muscular Dystrophy Treated in a Post-Marketing Setting

Sponsor: Sarepta Therapeutics, Inc. · Phase: PHASE4 · Area: RARE_ORPHAN · Target Enrollment: 20 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$13,184,000

Rescue Site Savings

+$8,693,200

Unlock Full NCT07542314 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07542314 Rescue Dossier →